A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

The goal of this clinical trial is to understand if a new drug called LNS8801 can safely treat patients with melanoma. The primary question to be answered is what is the average length of time during which melanoma does not grow or spread after starting treatment with LNS8801? Researchers will compare LNS8801 taken alone or LNS8801 taken together with another drug called pembrolizumab to other therapies as decided by the treating doctor. 135 patients will be randomly (like flipping a coin) placed in 3 treatment groups. In the first group (LNS8801 only) - Patients will take 125mg tablet of LN

Trial Details

NCT ID
NCT06624644
Phase
PHASE2 / PHASE3
Sponsor
Linnaeus Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • LNS8801
  • Pembrolizumab
  • Chemotherapy (dacarbazine or temozolomide)
  • Immunotherapy (Pembrolizumab)
  • Immunotherapy (nivolumab and relatlimab)
  • Immunotherapy (ipilimumab and nivolumab)
Locations (sample)
  • Newport Beach, California, United States|33.61891,-117.92895
  • San Francisco, California, United States|37.77493,-122.41942
  • Stanford, California, United States|37.42411,-122.16608
  • Aurora, Colorado, United States|39.72943,-104.83192
  • Denver, Colorado, United States|39.73915,-104.9847

Key Eligibility Criteria

  • Confirmed unresectable and/or metastatic cutaneous melanoma.
  • 2 copies of the fully functional form of GPER protein-coding sequence.
  • Eligible for and willing to receive 1 or more of the physician's choice (PC) therapies.
  • Able to swallow tablets.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →